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Marseille, FranceMahamadou Doutchi1, Piseth Seng1,2,3, Amélie Menard1,3, Line Meddeb1, Tarek Adetchessi4, Stephane Fuentes4,
Henry Dufour4 and Andreas Stein1,2,3
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France and 4) Service de Neurochirurgie, CHU de la Timone, Marseille, FranceAbstractThe incidence and signiﬁcant morbidity of vertebral osteomyelitis are increasing despite the progress of diagnosis competences. Among the
50 cases of vertebral osteomyelitis managed in our centers over the past 5 years, 84% of the cases were in men. The mean age was 55 years.
Sixty-two percent of patients had comorbidities and risk factors: diabetes mellitus (24%), malignancy (16%), intravenous drug use (10%) and
alcoholism (4%). A source of infection was identiﬁed in 66% of cases, including postvertebral surgery infection (18%) and hematogenous
infection (48%). The mean time to diagnosis was 36 days. Back pain were occurred in 90% of cases, fever (70%), neurologic deﬁcits
(40%), epidural abscesses (32%), completed vertebral bone destruction (26%) and psoas abscess (12%). A single organism was isolated in
92% of cases. Gram-positive bacteria were identiﬁed in 76% of cases, while Gram-negative bacilli (GNB) were found in 18% of cases. The
presence of GNB was signiﬁcantly associated with malignancy (p 0.041). The mean duration of antibiotic therapy was 123 days. Surgical
treatment was performed in 41 cases: spinal stabilization (26%), drainage of abscesses (32%) and relief of compression (40%). Residual
pain was found in 24% of cases, and neurologic sequelae in 22%. Cervical or thoracic localization was a risk factor for neurologic
compromise (p 0.042). The epidemiology of vertebral osteomyelitis has changed; an increase in malignancy that was signiﬁcantly
associated with vertebral osteomyelitis due to GNB has been observed. Our study shows that the rate of neurologic complications
remains high despite improved diagnostic capabilities and optimal treatment.
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E-mail: sengpiseth@yahoo.frIntroductionThe incidence of vertebral osteomyelitis has increased in recent
years, likely due to longer life expectancies, the increasingNew Microbes and New Infections © 2015 The Authors. Published by El
This is an open access artiprevalence of chronic disease, improved diagnosis and more
frequent use of indwelling intravascular catheters and immu-
nosuppressive therapies [1]. Vertebral osteomyelitis is associ-
ated with signiﬁcant morbidity, including prolonged need for
antimicrobial therapy and decreased functional status [2].
Vertebral osteomyelitis is mainly caused by hematogenous
seeding. Direct inoculation through iatrogenic procedures and
contiguous spread from adjacent infection are rare [3]. In a
systematic review, the source of infection was documented in
32% of the cases. However, details were presented for only
35% of the cases [4]. The urinary tract was the most frequently
presumed source of infection in 17% of the cases [4].New Microbe and New Infect 2015; 7: 1–7
sevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
http://dx.doi.org/10.1016/j.nmni.2015.04.008
2 New Microbes and New Infections, Volume 7 Number C, September 2015 NMNIThe mortality rate of vertebral osteomyelitis is decreased,
however neurologic compromise remains high. Approximately
one-third of survivors have experienced residual disabilities that
seriously affected their quality of life [5]. Despite improved
recognition of the disease, management strategies vary widely
across centers, particularly with regard to the choice and dura-
tion of antimicrobial treatment and the indication for surgical
intervention [1]. Previous studies have reported that the residual
back pain was more frequent in patient treated only by medical
treatment (64%) than those treated by surgery (26%) [6].
We retrospectively reviewed the clinical, microbial features
and outcome of vertebral osteomyelitis managed in an inter-
regional referral center for bone and joint infections in the
south of France.Materials and methodsTABLE 1. Population characteristics
Characteristic n (%)
Sex
Female 8 (16)
Male 42 (84)
Comorbidity and risk factor
Diabetes mellitus 12 (24)
Solid cancer, hematologic malignancy 8 (16)
Immunosuppressive therapy 4 (8)
Intravenous drug users 5 (10)
Alcoholism 2 (4)
Source of infection
Urinary tract infection 15 (30)
Postvertebral surgery with infection of
internal ﬁxation or another artiﬁcial device
9 (18)
Vascular catheter-related infection 5 (10)
Respiratory tract infection 4 (8)
Clinical presentation
Pain 45 (90)
Fever 35 (70)
Neurologic deﬁcits 20 (40)
Epidural abscess 16 (32)
Completed vertebral bone destruction 13 (26)
Psoas abscess 6 (12)
Endocarditis 3 (6)
Septic cerebral embolism 1 (2)
Pulmonary abscess 1 (2)
Localization
Cervical 5 (10)
Thoracic 13 (26)
Lumbar 29 (58)
Multiple localization 3 (6)This study design was approved by the review board of our
institute. We retrospectively reviewed the 50 cases of vertebral
osteomyelitis with positive culture managed between January
2007 and December 2012 from among the 3778 patients with
bone and joint infections (inpatients and outpatients >18 years
old) managed in an interregional referral center for bone and
joint infections in the south of France. This center is composed
of two neurosurgery units, four orthopedic surgery units, two
plastic surgery units and two infectious diseases units which
located in University hospitals of Marseille.
The diagnosis of vertebral osteomyelitis was based on patients’
medical history, including clinical evidence of infection based on
biologic and/or radiologic data, with two or more positive blood
cultures or two or more positive cultures from deep samples
from surgical or percutaneous biopsy to exclude contaminating
bacteria as previously described [7]. Three blood cultures, three
deep samples from percutaneous biopsy and ﬁve deep samples
from surgical biopsy on average per patient were taken.
After incubation, the bacteria species was identiﬁed through
conventional phenotypic identiﬁcation or matrix-assisted laser
desorption-ionization time-of-ﬂight mass spectrometry
(MALDI-TOF MS) (Brüker Daltonik) as previously described
[7]. A complete 16S rRNA gene sequencing and real-time PCR
assays targeting Staphylococcus aureus performed on bacteria
colony for the unknown bacteria identiﬁed through MALDI-
TOF MS and on deep samples which were negative at cul-
ture, as previously described [7,8]. All the cases of vertebral
osteomyelitis without bacterial documented by culture and
biology molecular identiﬁcation were excluded. We evaluated
each patient’s medical history, assessing factors such as de-
mographic characteristics, comorbidities, risk factors associated
with vertebral osteomyelitis and clinical characteristics. RoutesNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceof entry and dissemination for vertebral osteomyelitis were
reviewed. We also recorded the location of infection and the
presence of any orthopedic prostheses or devices. We
reviewed the antimicrobial and/or surgical treatment ap-
proaches used in each case.
Data analyses were performed using IBM® SPSS® Statistics
software v.20.0. Proportions were compared using two-tailed
chi-squared tests. A value of p < 0.05 was considered statisti-
cally signiﬁcant.ResultsClinical characteristics
Among the 50 cases of vertebral osteomyelitis which repre-
sented 2.6% of 3778 patients with bone and joint infection
managed in our centers overs 6-year study period, 42 (84%)
were men, resulting in a male: female ratio of 5.25:1. The mean
age of patients was 55 (±15 years, range 29–92). Thirty-one
cases (62%) had comorbidities and risk factors such as dia-
betes mellitus in 12 cases (24%), solid cancer or hematologic
malignancy in eight cases (16%), intravenous drug use (IDU) in
ﬁve cases (10%) and alcoholism in two cases (4%) (Table 1).
Eight cases of vertebral osteomyelitis co-occurred with malig-
nancy, including three cases of head and neck cancer, two cases
of hematologic malignancy, two cases of digestive cancer and
one case of lung cancer.
Source of infection was identiﬁed in 33 cases (66%), including
15 cases (30%) of urinary tract infection, nine cases (18%) ofEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 1–7
nses/by-nc-nd/4.0/)
FIG. 1. Diagnostic tools of vertebral
osteomyelitis.
NMNI Doutchi et al. Epidemiology of vertebral osteomyelitis 3after vertebral surgery with infection of internal ﬁxation or
another artiﬁcial device, ﬁve cases (10%) of vascular catheter-
related infection and four cases (8%) of respiratory tract
infection (Table 1).
The mean time from symptom onset to diagnosis of the 50
cases of vertebral osteomyelitis in our study was 36 days (±20
days, range 10–77 days). Forty-two cases (78%) were diag-
nosed within the ﬁrst month of symptom onset. Back pain,
which occurred in 45 cases (90%), was the most frequent
symptom, followed by fever in 35 cases (70%), neurologic
deﬁcits in 20 cases (40%), epidural abscesses in 16 cases (32%),
complete vertebral bone destruction in 13 cases (26%) and
psoas abscess in six cases (12%). Concomitant infections,
including endocarditis, pulmonary abscess and brain abscess,
were observed in three cases, one case and one case, respec-
tively. Among the 20 cases with neurologic deﬁcits, spinal cord
compression was observed in 11 cases (22%), caudal equine
compression in ﬁve cases (10%) and isolated nerve root com-
pressions in four cases (8%). We also recorded a case of
femoral neuropathy and a case of paraplegia.
Vertebral osteomyelitis presented as a disease of a single
region of the spine in 94% of cases. The lumbar region was
affected in 29 cases (58%), followed by the thoracic region in 13
cases (26%) and cervical regions in ﬁve cases (10%). We
observed three cases (6%) that affected multiple vertebra.
Among 50 cases of vertebral osteomyelitis, 45 cases (90%)
had two or more positive vertebral biopsy ﬁndings, and 33
cases (66%) had two or more positive blood cultures. Twenty-
eight cases (56%) had both two or more positive blood cultures
and two or more positive vertebral biposy ﬁndings with theNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on b
This is an open access artisame microorganism. Five cases (10%) of vertebral osteomye-
litis were diagnosed based on positive blood cultures alone.
Among 45 positive vertebral biopsy ﬁndings, surgical biopsy was
performed in 25 cases (56%), percutaneous biopsy in six cases
(13%) and both in 14 cases (31%; Fig. 1).
Microbiologic characteristics
A single organism was isolated from 37 cases (92%), while
polymicrobial infection was reported in three cases (8%).
Aerobic Gram-positive bacteria were found in 38 cases (76%),
while aerobic Gram-negative bacilli (GNB) represented 18% of
cases. Fifteen bacteria species have been identiﬁed and include
Staphylococcus aureus (18 cases), S. epidermidis (10), S. hominis
(1), Streptococcus agalactiae (5), S. mitis (1), S. sanguinis (1),
Enterococcus faecalis (2), Klebsiella pneumoniae (5), K. oxytoca (1),
Escherichia coli (2), Serratia marcescens (1), Pseudomonas aerugi-
nosa (1), Peptoniphilus harei (1), Brevibacterium casei (1), Propio-
nibacterium acnes (1) and Mycobacterium tuberculosis (3)
(Table 2). All of 54 isolates, 11 (20%) were identiﬁed by con-
ventional phenotypic identiﬁcation and 43 (86%) were identiﬁed
by MALDI-TOF MS. Two species (Brevibacterium casei and
Peptoniphilus harei) were identiﬁed by MALDI-TOF MS and
conﬁrmed by molecular identiﬁcation.
Coagulase-negative staphylococci (CNS) was identiﬁed in
22% of our cases which was frequently occurred in post-
operative implant-associated vertebral osteomyelitis than he-
matogenous native vertebral osteomyelitis (5/11 vs. 4/40, p
0.017). Six S. epidermidis isolates were identiﬁed in both blood
culture and vertebral biopsy samples; one S. epidermidis isolate
was isolated from blood culture; and one S. hominis was isolatedehalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 1–7
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licefrom vertebral biopsy samples. All of the nine cases (18%) of
vertebral osteomyelitis caused by aerobic GNB were occurred
in the patients who had native vertebral osteomyelitis. Six of
nine cases of aerobic GNB vertebral osteomyelitis were
localized in lumbar compared to 25 of 41 cases of non-GNB
vertebral osteomyelitis (p 1.000).
Of 18 S. aureus isolates, sensibility reduced to methicillin was
found in three cases (17%), quinolones (three cases; 17%),
rifampicin (one case, 6%), clindamycin (two cases, 11%), ami-
noglycoside (one case, 6%) and fusidic acid (two cases, 11%).
No resistant to cotrimoxazole was found in S. aureus isolates
(Table 2).
Among 11 cases of CNS isolates, methicillin resistant was
found in ﬁve cases (45%), quinolones resistant (ﬁve cases; 45%),
cotrimoxazole resistant (three cases, 27%), clindamycin resis-
tant (three cases, 27%), aminoglycoside resistant (three cases,
27%) and fusidic acid resistant (ﬁve cases, 45%). No resistant to
rifampicin was found in CNS isolates. No relevant of antimi-
crobial resistant found among streptococci isolates (Table 2).
Among nine isolates of Enterobacteriaceae, sensibility
reduced to ceftriaxone were found in two cases (22%), ami-
noglycoside (one case, 11%), quinolones (four cases, 44%) and
cotrimoxazole (two cases, 22%) (Table 2).
Medical and surgical treatment
The antibiotics that were most frequently used in our series
were rifampicin, quinolones, amoxicillin and ceftriaxone, which
were used in 25 cases (50%), 24 cases (48%), 12 cases (24%)
and ﬁve cases (10%), respectively. Combination of antibiotic
treatment was recorded in 41 cases (82%) and typically
involved two antibiotics (37 cases, 74%). The combination of
rifampicin and quinolones was used in 14 cases (28%). The
mean overall duration of antibiotic treatment was 123 days
(±44 days, range 90–183). Nine cases (18%) were administered
only medical treatment without require surgery treatment.
Forty-one cases (82%) were treated by surgical treatment
included spinal stabilization in 13 cases (26%), drainage of ab-
scesses in 16 cases (32%) and relief of compression in 20 cases
(40%). Out of the 50 cases of vertebral osteomyelitis, the three
cases of vertebral osteomyelitis caused by M. tuberculosis were
treated by 9 months of antituberculosis drugs.
Clinical outcome
In 45 of 50 cases (90%), patients received complete follow-up
until the end of treatment. The mean duration of follow-up for
these cases was 36 months (±20 months; range 9–77). Four
patients (8.5%) died; death was due to malignancy in three cases
and to septic shock in one case. Four cases were lost during the
follow-up treatment period. Thirty-six cases (78%) were dis-
charged without any neurologic sequelae included eight cases inEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 1–7
nses/by-nc-nd/4.0/)
NMNI Doutchi et al. Epidemiology of vertebral osteomyelitis 5the group of medical treatment only and 28 cases in the surgery
treatment group. Residual pain was observed in 11 cases (24%).
Neurologic sequelae were observed in 10 cases (22%), including
impaired mobility in nine cases (20%) and motor weakness in one
case (2%). One case of neurologic sequelae was in the group of
medical treatment only; and nine cases were in the surgery
treatment group. The presence of neurologic sequelae was not
signiﬁcantly different between medical treatment groups and
surgical treatment groups (p 0.659).
A recurrence of the symptoms of infection after apparent
resolution developed after discharge in two patients (4%); thus,
two relapses occurred. The intervals between the initial illness
and relapse were 1 and 12 months. Relapse was conﬁrmed in
the two affected patients by positive cultures of samples ob-
tained from bone, abscesses and blood. S. epidermidis strains
isolated from both patients during the ﬁrst episode were also
recovered during relapse. In one patient, K. pneumoniae was
isolated concomitantly from the infected intervertebral disk
space. This patient exhibited severe destructive changes and
deformities of the vertebrae that might have suppressed healing
and facilitated the persistence of microorganisms, despite
antibiotic treatment.
The mean time between the onset of symptoms and diag-
nosis was signiﬁcantly longer for cases with neurologic sequelae
(n = 10) than for cases that went into remission without
neurologic sequelae (n = 35), i.e. 46 days (±23 days, range
14–76 days, 95% conﬁdence interval 30–62) vs. 32 days (±19
days, range 10–77 days, 95% conﬁdence interval 25–38),
respectively (p 0.049).
The subgroup of 20 cases (40%) of neurologic deﬁcits
comprised ﬁve cases (25%) of S. aureus, four cases (25%) of
S. epidermidis, two cases (10%) of streptococci and eight cases
(40%) of Gram-negative bacillus infections. Vertebral osteo-
myelitis associated with GNB was also signiﬁcantly associated
with malignancy (p 0.041), including two cases of hematologic
malignancy, one case of head and neck cancer, one case of
digestive cancer and one case of lung cancer.
The frequency of motor dysfunction was highest among
patients with infections of the lumbar spine (40% of cases),
followed by infections of the thoracic (35%) and cervical spine
(15%). In addition, spinal cord compression was signiﬁcantly
more frequent in vertebral osteomyelitis of the cervical and
thoracic spine than in that of the lumbar spine (p 0.049).DiscussionHerein, we presented a series of 50 cases of microbiologically
proven vertebral osteomyelitis gathered over a 6-year period
for which a long-term outcome was determined. The medianNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on b
This is an open access artitime to diagnosis in the present study was 30 days, which is
shorter than the time to diagnosis observed in a previous study
(6 weeks) [3]. This phenomenon likely results from the fact that
magnetic resonance imaging (MRI) is now more easily acces-
sible. Almost all affected persons were asymptomatic for
several days before diagnosis [9–12]. The clinical picture of
vertebral osteomyelitis was often nonspeciﬁc, and for this
reason, imaging has become an essential component of the
diagnostic process.
Surgical biopsy was relevant to the microbiologic diagnosis of
vertebral osteomyelitis in from 58% to 79% of cases [4]. A
recent study reported that second percutaneous biopsies allow
microbiologic diagnosis in 80% of cases [13]. In our study,
microbiologic diagnosis of vertebral osteomyelitis was accom-
plished by surgical biopsy in 39 cases (78%), and positive cul-
tures of computerized tomography-guided punctures preceded
surgical treatment in 14 of 20 cases (70%). Eighty-two percent
of our patients needed surgical treatment, such as spinal sta-
bilization (26%), drainage of abscesses (32%) and relief of
compression (40%); a microbiologic diagnosis is made in 90% of
patients using surgical biopsy tissue because of this high rate of
surgical intervention.
Sixty-six cases of vertebral osteomyelitis have positive blood
culture in our study, which was comparable to the rate
observed in previous studies [4,14], but lower than that of the
biopsy samples. However, in our series, blood cultures taken
before biopsy were used to diagnose ﬁve cases of vertebral
osteomyelitis that had negative vertebral biopsy ﬁndings.
Another beneﬁt of positive blood cultures was that they
encouraged us to look for potential complications, such as
infective endocarditis, pulmonary abscess and septic cerebral
embolism related to vertebral osteomyelitis in our series.
S. aureus remains the predominant causative microorganism
(36%) in our series; this ﬁnding was consistent with the results of
previous studies (35 to 75%) [15–18]. Thus, coagulase-negative
staphylococci have been recorded in 22% of our patients, which
is a higher rate than that observed previous studies (3 to 15%)
[15–17,19], likely reﬂecting the high proportion of hospital-
acquired infections included in our series: 38% of our patients
presented with hospital-acquired infections (postvertebral sur-
gery infections and vascular catheter-related infections). A
similarly high proportion of hospital-acquired infections verte-
bral osteomyelitis has been previously reported [20].
K. pneumoniae was the predominant etiologic agent of in-
fections with GNB in our series, in contrast with previous
studies [4,21]. We have also observed an increase in Strepto-
cocci (14%) and anaerobic bacteria that may be indicative of
epidemiologic change.
Forty-eight percent of vertebral osteomyelitis resulted from
hematogenous dissemination from a remote site of infection, asehalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 1–7
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
6 New Microbes and New Infections, Volume 7 Number C, September 2015 NMNIwas observed with vascular catheter-related infections (10%),
respiratory tract infections (8%) and urinary tract infections
(20%). Microbes can spread from the urinary system and seed
the vertebrae, leading to the development of osteomyelitis via
Batson’s plexus [22].
Previous studies have suggested that the factors affecting the
occurrence of vertebral osteomyelitis include prior infection,
diabetes mellitus, rheumatic disease, immunodeﬁciency, IDU,
alcoholism, and vertebral compression due to malignant
metastasis [3]. The underlying diseases associated with verte-
bral osteomyelitis in this study were similar to those previously
reported, with diabetes mellitus found in 24% of patients, fol-
lowed by cancer (16%), IDU (10%) and corticosteroid treat-
ment (7%) [15,19,21,23–25].
Among the well-known comorbidity and risk factors for
vertebral osteomyelitis, we observed a signiﬁcant association
between malignancy and infection with GNB. This observation
has not been reported in previous studies [1]. No association
was found between bacterial species and clinical outcome.
Intravenous antibiotics were the most prescribed antibiotics
in some studies [21,24,26]. The high bioavailability and adequate
diffusion of rifampicin, quinolone, clindamycin, and fusidic acid
have allowed oral administration early in the course of treat-
ment [21,27]. Oral treatments with rifampicin, quinolones and
amoxicillin were used in 25 (50%), 24 (48%) and 12 (24%) cases
in our series, respectively. Twenty-eight percent of the cases in
our series were treated with a combination of rifampicin and
quinolones.ConclusionsThe epidemiology of vertebral osteomyelitis may be changing,
with an increase in malignancy that is signiﬁcantly associated
with GNB in vertebral osteomyelitis. In our study, the rate of
neurologic complications remains high despite improved diag-
nosis and optimal treatment. Vertebral osteomyelitis requires a
multidisciplinary approach to improve the prognosis.Conﬂict of interestNone declared.AcknowledgementsThe authors thank C. Leautier and C. Peruffo for technical
support in data extraction.New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
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